Tirzepatide + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Sleep Apnea
Conditions
Obstructive Sleep Apnea, Obesity
Trial Timeline
Jun 21, 2022 โ Mar 29, 2024
NCT ID
NCT05412004About Tirzepatide + Placebo
Tirzepatide + Placebo is a phase 3 stage product being developed by Eli Lilly for Obstructive Sleep Apnea. The current trial status is completed. This product is registered under clinical trial identifier NCT05412004. Target conditions include Obstructive Sleep Apnea, Obesity.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06962280 | Phase 3 | Active |
| NCT06914895 | Phase 3 | Active |
| NCT06191848 | Approved | Recruiting |
| NCT06439277 | Phase 3 | Recruiting |
| NCT05708859 | Approved | Recruiting |
| NCT06075667 | Phase 3 | Active |
| NCT06037252 | Phase 2 | Active |
| NCT06047548 | Phase 3 | Active |
| NCT05963022 | Phase 3 | Completed |
| NCT05536804 | Phase 2 | Active |
| NCT05696847 | Phase 1 | Completed |
| NCT05691712 | Phase 3 | Completed |
| NCT05556512 | Phase 3 | Active |
| NCT05412004 | Phase 3 | Completed |
| NCT05024032 | Phase 3 | Completed |
| NCT04235959 | Phase 1 | Completed |
| NCT04081337 | Phase 1 | Completed |
| NCT04050553 | Phase 1 | Completed |
| NCT04184622 | Phase 3 | Completed |
| NCT04166773 | Phase 2 | Completed |
Competing Products
20 competing products in Obstructive Sleep Apnea